Pelvic ultrasound
OtherPelvic or vaginal ultrasound
NCT Number: NCT04746053
The main objective of this study is to study the ovarian function of patients with hepatocyte nuclear factor-1beta (HNF1B) abnormality, followed in the reference centers of Toulouse and Paris University Hospitals. The secondary objectives are to know the gynecological profile of these patients.
A dosage of anti-mullerian hormone (AMH) will be added to the usual balance, whatever the phase of the cycle and a pelvic ultrasound will be performed by the same operator by center. Patients will be received in a dedicated consultation to complete a questionnaire on gynecological and obstetric history, as well as their personal and family history. There will be no gynecological examination during this consultation.
Looking for future studies?
Notify Me12 year and older
Female
Interventional
Not applicable
Necker Hospital, Paris, France
HNF1B mutations can be responsible for genital malformations associated with renal development abnormalities. HNF1b is also a candidate gene involved in the development of the renal tract and the Mullerian system but there is no data in the literature regarding the ovarian function and clinical gynecological profile of these patients.
The main objective of this study is to study the ovarian function of patients with HNF1B abnormality, followed in the reference centers of Toulouse and Paris University Hospitals. The secondary objectives are to know the gynecological profile of these patients.
A dosage of AMH will be added to the usual balance, whatever the phase of the cycle and a pelvic ultrasound will be performed. Patients will be received in a dedicated consultation to complete a questionnaire on gynecological and obstetric history, as well as their personal and family history. There will be no gynecological examination during this consultation.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Pelvic or vaginal ultrasound
blood sample (5ml)
Time frame: day 1
serum level of antimullerian hormone levels in ng/mL
Time frame: day 1
ultrasound (pelvic or vaginal) will allow the team to look at whether or not there is a genital defect and the type of defect.
University Hospital, Toulouse
Other
Study of Ovarian Function and Gynecological Profile of Patients Carrying a Pathogenic Variant of the HNF1B Gene (GYN-HNF1)
Acronym: GYN-HNF1
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT01462890
Abdominal Neoplasms, Adnexal Diseases
Aalborg, Denmark
View Trial DetailsNCT03562897
Adnexal Diseases, Carcinoma
Havana, Cuba
View Trial DetailsNCT01526668
Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications
Eksjö, Jonkopings Län, Sweden
View Trial DetailsNCT04858919
Behavior, Diagnoses Disease
Cairo, Egypt
View Trial Details